James M. Nelson

6.1k total citations · 2 hit papers
58 papers, 4.4k citations indexed

About

James M. Nelson is a scholar working on Organic Chemistry, Inorganic Chemistry and Oncology. According to data from OpenAlex, James M. Nelson has authored 58 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Organic Chemistry, 16 papers in Inorganic Chemistry and 12 papers in Oncology. Recurrent topics in James M. Nelson's work include Organometallic Complex Synthesis and Catalysis (15 papers), Synthesis and characterization of novel inorganic/organometallic compounds (13 papers) and HER2/EGFR in Cancer Research (10 papers). James M. Nelson is often cited by papers focused on Organometallic Complex Synthesis and Catalysis (15 papers), Synthesis and characterization of novel inorganic/organometallic compounds (13 papers) and HER2/EGFR in Cancer Research (10 papers). James M. Nelson collaborates with scholars based in United States, Canada and New Zealand. James M. Nelson's co-authors include Ian Manners, David W. Fry, Wilbur R. Leopold, Alexander J. Bridges, Harry R. Allcock, Alan J. Lough, Alan J. Kraker, Amy McMichael, William A. Denny and Charles H. Honeyman and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of the American Chemical Society.

In The Last Decade

James M. Nelson

57 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase

1994 684 citations David W. Fry, Alan J. Kraker et al. profile →
PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

2007 598 citations Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Cancer Research profile →

Peers

Countries citing papers authored by James M. Nelson

Since Specialization

Citations

This map shows the geographic impact of James M. Nelson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James M. Nelson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James M. Nelson more than expected).

Fields of papers citing papers by James M. Nelson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James M. Nelson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James M. Nelson. The network helps show where James M. Nelson may publish in the future.

Co-authorship network of co-authors of James M. Nelson

This figure shows the co-authorship network connecting the top 25 collaborators of James M. Nelson. A scholar is included among the top collaborators of James M. Nelson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James M. Nelson. James M. Nelson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Why We Need the Demonic: A Phenomenological Analysis of Negative Religious Experience 2018 ·Open Theology ·James M. Nelson, (unknown)	2
2	Serum and glucocorticoid-regulated kinase 1 promotes vascular smooth muscle cell proliferation via regulation of β-catenin dynamics 2014 ·Cellular Signalling ·Wei Zhong, (unknown), Yan Xiao, James M. Nelson, Liliana Hernández, Minerva T. Garcia-Barrio, Sharon Francis	13
3	A History of Psychology of Religion in the West: Implications for Theory and Method 2011 ·Pastoral Psychology ·James M. Nelson	6
4	PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib breakdown → 2007 ·Cancer Research ·Jeffrey A. Engelman, Kreshnik Zejnullahu, (unknown), Eugene Lifshits, Andrea J. Gonzales, Takeshi Shimamura, Feng Zhao, Patrick W. Vincent, George N. Naumov, James E. Bradner, Irene W. Althaus, Leena Gandhi, Geoffrey I. Shapiro, James M. Nelson, John V. Heymach, Matthew Meyerson, Kwok‐Kin Wong, Pasi A. Jänne	598
5	Philosophical Issues in Psychology and Religion: An Introduction 2006 ·Journal of Psychology and Theology ·James M. Nelson, Brent D. Slife	11
6	Hermeneutics and Dialogue as Tools toward Integration: Babies and Bathwater, Problems and Solutions 2006 ·Journal of Psychology and Theology ·James M. Nelson	1
7	Akt, MAPK (Erk1/2), and p38 Act in Concert to Promote Apoptosis in Response to ErbB Receptor Family Inhibition 2001 ·Journal of Biological Chemistry ·James M. Nelson, David W. Fry	93
8	Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. 2000 ·Journal of Medicinal Chemistry ·Jeff B. Smaill, Gordon W. Rewcastle, Alexander J. Bridges, Hairong Zhou, H. D. Hollis Showalter, David W. Fry, James M. Nelson, (unknown), William L. Elliott, Patrick W. Vincent, (unknown), Joseph A. Loo, Kenneth D. Greis, O. Helen Chan, Eric L. Reyner, Elke Lipka, William A. Denny	12
9	Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor 2000 ·Journal of Medicinal Chemistry ·Jeff B. Smaill, H. D. Hollis Showalter, Hairong Zhou, Alexander J. Bridges, Dennis J. McNamara, David W. Fry, James M. Nelson, (unknown), Patrick W. Vincent, Bill J. Roberts, William L. Elliott, William A. Denny	82
10	Recent developments in the 'living' cationic, ambient temperature synthesis of polyphosphazenes with controlled architectures 1998 ·James M. Nelson, Harry R. Allcock, Ian Manners	0
11	Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor 1998 ·Proceedings of the National Academy of Sciences ·David W. Fry, Alexander J. Bridges, William A. Denny, Annette M. Doherty, Kenneth D. Greis, James L. Hicks, Kenneth E. Hook, Paul R. Keller, Wilbur R. Leopold, Joseph A. Loo, Dennis J. McNamara, James M. Nelson, (unknown), Jeff B. Smaill, Susanne Trumpp-Kallmeyer, Ellen M. Dobrusin	344
12	Cytoskeletal and Morphological Changes Associated with the Specific Suppression of the Epidermal Growth Factor Receptor Tyrosine Kinase Activity in A431 Human Epidermoid Carcinoma 1997 ·Experimental Cell Research ·James M. Nelson, David W. Fry	15
13	Ambient-Temperature Direct Synthesis of Poly(organophosphazenes) via the “Living” Cationic Polymerization of Organo-Substituted Phosphoranimines 1997 ·Macromolecules ·Harry R. Allcock, James M. Nelson, Scott D. Reeves, Charles H. Honeyman, Ian Manners	95
14	Polyphosphazene Block Copolymers via the Controlled Cationic, Ambient Temperature Polymerization of Phosphoranimines 1997 ·Macromolecules ·Harry R. Allcock, Scott D. Reeves, James M. Nelson, (unknown), Ian Manners	94
15	Thermal Ring‐Opening Polymerization of Hydrocarbon‐Bridged [2]Ferrocenophanes: Synthesis and Properties of Poly(ferrocenylethylene)s and Their Charge‐Transfer Polymer Salts with Tetracyanoethylene 1997 ·Chemistry - A European Journal ·James M. Nelson, Paul Nguyen, Ruth Petersen, (unknown), Peter M. Macdonald, Alan J. Lough, Ian Manners, (unknown), John E. Greedan, Stephen Barlow, Dermot O’Hare	63
16	Biochemical and antiproliferative properties of 4-[Ar(alk)ylamino]pyridopyrimidines, a new chemical class of potent and specific epidermal growth factor receptor tyrosine kinase inhibitor 1997 ·Biochemical Pharmacology ·David W. Fry, James M. Nelson, (unknown), Paul R. Keller, Gordon W. Rewcastle, William A. Denny, Hairong Zhou, Alexander J. Bridges	55
17	Synthesis, characterisation and structure of a strained ring-tilted bis(indenyl)iron complex 1997 ·Journal of Organometallic Chemistry ·(unknown), Stephen Barlow, (unknown), Dermot O’Hare, (unknown), James M. Nelson, Ian Manners	25
18	Tyrosine Kinase Inhibitors. 6. Structure−Activity Relationships among N- and 3-Substituted 2,2‘-Diselenobis(1H-indoles) for Inhibition of Protein Tyrosine Kinases and Comparative in Vitro and in Vivo Studies against Selected Sulfur Congeners 1997 ·Journal of Medicinal Chemistry ·H. D. Hollis Showalter, Anthony D. Sercel, (unknown), (unknown), (unknown), William L. Elliott, David W. Fry, Alan J. Kraker, (unknown), Gina H. Lu, Charles Watson Moore, James M. Nelson, Bill J. Roberts, Patrick W. Vincent, William A. Denny, Andrew M. Thompson	57
19	Synthese und Ringöffnungspolymerisation hochgespannter [2]Ruthenocenophane 1994 ·Angewandte Chemie ·James M. Nelson, Alan J. Lough, Ian Manners	36
20	Synthesis, Structures, and Polymerization Behavior of Disilane-Bridged and Bis(disilane)-Bridged [2]Ruthenocenophanes 1994 ·Organometallics ·James M. Nelson, Alan J. Lough, Ian Manners	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact